ATRA
Atara Biotherapeutics, Inc.
$9.76
-0.19 (-1.86%)
At close · Jul 10
Market Cap
$87.94M
Shares
9,010,172
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$120.77M
-6.3%
FY2025
Net Income
$32.69M
+138.3%
FY2025
Operating Margin
29.69%
+94.4pp
FY2025
Diluted EPS
$2.57
+122.5%
FY2025
Operating Cash Flow
-$50.94M
+25.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $23.14M | $120.77M | $128.94M | $8.57M | $63.57M | — | — | — | — | — | — | — | — | — | |
| $10.18M | $37.45M | $151.48M | $224.79M | $272.53M | $282M | $244.65M | $216.1M | $167.46M | $81.21M | $56.51M | $41.62M | $15.45M | $4.31M | |
| $18.38M | $26.25M | $39.89M | $50.91M | $71.55M | $78.8M | $64.4M | $79.58M | $69.65M | $40.33M | $24.73M | $16.83M | $12.71M | $3.76M | |
| — | $2.12M | $5.05M | $4.83M | $5.65M | $9.35M | $8.33M | $7.07M | $3.73M | $956K | $383K | $48K | — | — | |
| $2.8M | $12.61M | $5.11M | $6.73M | $5.96M | — | — | — | — | — | — | — | — | — | |
| $313.46M | — | — | — | $344.09M | $360.8M | $309.05M | $295.68M | $237.11M | $121.53M | $81.24M | $58.45M | $28.16M | $8.62M | |
| $29.45M | $84.91M | $212.38M | $284.58M | $344.09M | — | — | — | — | — | — | — | — | — | |
| -$6.31M | $35.86M | -$83.44M | -$276.01M | -$280.51M | -$340.46M | -$309.05M | -$295.68M | -$237.11M | -$121.53M | -$81.24M | -$58.45M | -$28.16M | -$8.62M | |
| — | 29.69% | -64.71% | -3219.48% | -441.25% | — | — | — | — | — | — | — | — | — | |
| — | $37.98M | -$78.39M | -$271.18M | -$274.86M | -$331.12M | -$300.72M | -$288.61M | -$233.38M | -$120.58M | -$80.86M | -$58.4M | — | — | |
| $3.61M | $3.79M | $4.62M | $5.29M | $373K | — | — | — | — | — | — | — | — | — | |
| -$23K | -$34K | $528K | -$246K | -$700K | $367K | $2.45M | $4.72M | $6.37M | $2.03M | $2.2M | $1.22M | $125K | $12K | |
| — | — | — | $0 | $50.24M | $0 | $0 | — | — | — | — | — | — | — | |
| -$9.44M | $32.72M | -$85.42M | -$276.11M | -$228.29M | -$340.1M | -$306.61M | -$290.96M | -$230.74M | -$119.51M | -$79.04M | -$57.23M | -$28.03M | -$8.6M | |
| $31K | $31K | -$12K | $15K | $12K | $46K | $15K | $12K | -$44K | -$14K | $10K | -$9000 | -$25K | $170K | |
| -$9.47M | $32.69M | -$85.4M | -$276.13M | -$228.3M | -$340.14M | -$306.62M | -$290.98M | -$230.7M | -$119.49M | -$79.05M | -$57.22M | -$28.01M | -$8.77M | |
| — | 27.07% | -66.23% | -3220.88% | -359.12% | — | — | — | — | — | — | — | — | — | |
| -$9.47M | $32.68M | -$85.19M | -$274.26M | -$230M | -$340.81M | -$306.54M | -$290.42M | -$230.89M | -$119.46M | -$78.71M | -$57.64M | -$28.11M | -$8.77M | |
| USD/shares | — | $2.61 | -$11.41 | -$65.19 | -$56.00 | -$90.75 | -$103.75 | — | — | — | — | — | — | — |
| USD/shares | — | $2.57 | -$11.41 | -$65.19 | -$56.00 | -$90.75 | -$103.75 | — | — | — | — | — | — | — |
| shares | — | 12.54M | 7.49M | 4.24M | 4.08M | 3.75M | 2.96M | 2.05M | 1.75M | 1.19M | 1.15M | 1.02M | 199.44K | 38.63K |
| shares | — | 12.72M | 7.49M | 4.24M | 4.08M | 3.75M | 2.96M | 2.05M | 1.75M | 1.19M | 1.15M | 1.02M | 199.44K | 38.63K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.05×
EV/EBIT
—
Biotechnology median 25.73×
P/E (TTM)
—
Biotechnology median 7.68×